世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界のスタチン市場 2019-2023年

Global Statin Market 2019-2023

IRTNTR30254

 

出版社 出版年月電子版価格 ページ数
TechNavio
テクナビオ
2018年11月US$2,500
シングルユーザライセンス
117

サマリー

この調査レポートは世界のスタチン市場を分析・予測したTechNavioの市場調査報告書です。

Description

About this market


The increasing statin use will help the market grow at a steady rate. In the US and the UK, people aged 40 and above are recommended to monitor their cholesterol level. Statins are considered an evidence-based treatment for high risk patients with elevated cardiovascular disorder. Technavio’s analysts have predicted that the statin market will register a CAGR of over 2% by 2023.

Market Overview


Rising prevalence of hypercholesterolemia
The rising prevalence of hypercholesterolemia is fueling the demand for generic cholesterol medications. Cardiovascular disease is one of the primary causes of mortality in Western countries.
Fierce generic competition
Patient expiration is a major challenge for companies developing branded drugs as it provides an opportunity for the development of generic drugs.
For the detailed list of factors that will drive and challenge the growth of the statin market during the 2019-2023, view our report.

Competitive Landscape


The market appears to be fragmented and with the presence of several companies including AstraZeneca and Merck the competitive environment is quite intense. Factors such as the increasing statin use and the rising prevalence of hypercholesterolemia, will provide considerable growth opportunities to statin manufactures. AstraZeneca, Merck, Pfizer, and Novartis are some of the major companies covered in this report.

‘With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies. Many established statin manufacturers are vying for their share of the global statin market, and the new players must differentiate themselves to gain vital traction over their competitors.’



目次

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Pipeline
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: MARKET SEGMENTATION BY TYPE
- Market segmentation by type
- Comparison by type
- Synthetic statins - Market size and forecast 2018-2023
- Natural statins - Market size and forecast 2018-2023
- Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: MARKET SEGMENTATION BY APPLICATION
- Dyslipidemia
- Others
PART 09: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Americas - Market size and forecast 2018-2023
- EMEA - Market size and forecast 2018-2023
- APAC - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 14: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- AstraZeneca
- Merck
- Novartis
- Pfizer
PART 15: APPENDIX
- Research methodology
- List of abbreviations
PART 16: EXPLORE TECHNAVIO

?
Exhibit 01: Global CVD treatment market
Exhibit 02: Segments of global CVD treatment market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: List of statins evaluated in late-stage clinical trials
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: List of some synthetic statins
Exhibit 21: Synthetic statins - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Synthetic statins - Year-over-year growth 2019-2023 (%)
Exhibit 23: Examples of natural statins
Exhibit 24: Natural statins - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Natural statins - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by type
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 32: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 34: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 38: Status of generic availability in US
Exhibit 39: Impact of generics on sales of branded products
Exhibit 40: Potential statin-drug interactions
Exhibit 41: Commonly occurring side effects of some statins
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Mobile apps for cholesterol management
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: AstraZeneca - Vendor overview
Exhibit 50: AstraZeneca - Business segments
Exhibit 51: AstraZeneca - Organizational developments
Exhibit 52: AstraZeneca - Geographic focus
Exhibit 53: AstraZeneca - Key offerings
Exhibit 54: Merck - Vendor overview
Exhibit 55: Merck - Business segments
Exhibit 56: Merck - Organizational developments
Exhibit 57: Merck - Geographic focus
Exhibit 58: Merck - Segment focus
Exhibit 59: Merck - Key offerings
Exhibit 60: Novartis - Vendor overview
Exhibit 61: Novartis - Business segments
Exhibit 62: Novartis - Organizational developments
Exhibit 63: Novartis - Geographic focus
Exhibit 64: Novartis - Segment focus
Exhibit 65: Novartis - Key offerings
Exhibit 66: Pfizer - Vendor overview
Exhibit 67: Pfizer - Business segments
Exhibit 68: Pfizer - Organizational developments
Exhibit 69: Pfizer - Geographic focus
Exhibit 70: Pfizer - Segment focus
Exhibit 71: Pfizer - Key offerings

?
?


 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る